Sinotherapeutics Inc. (SHA:688247)

China flag China · Delayed Price · Currency is CNY
9.41
-0.11 (-1.16%)
At close: Jul 3, 2026
Market Cap4.23B -8.1%
Revenue (ttm)432.19M -15.1%
Net Income43.56M -65.2%
EPS0.10 -64.3%
Shares Out 449.00M
PE Ratio93.49
Forward PEn/a
Dividend0.04 (0.37%)
Ex-Dividend DateJun 26, 2026
Volume13,663,647
Open9.45
Previous Close9.52
Day's Range9.19 - 9.80
52-Week Range7.02 - 13.28
Beta0.12
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride... [Read more]

Sector Healthcare
Founded 2012
Employees 319
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688247
Full Company Profile

Financial Performance

In 2025, Sinotherapeutics's revenue was 446.57 million, a decrease of -12.71% compared to the previous year's 511.62 million. Earnings were 47.48 million, a decrease of -62.82%.

Financial Statements